NOVARTIS AG ADR (NVS) is drawing unusual attention today. Our newswire has captured 6 stories on NVS across 2 sources in the last 36 hours, with AI sentiment reading bearish (avg 36/100).
Novartis AG ADR (NVS) fell 13.93% to $137.70 in a session marked by a significant blow to its drug development pipeline. The stock’s worst day in over two decades came after the company announced the failure of its experimental cholesterol drug del-desiran in a late-stage trial. This setback has raised concerns about the broader Lp(a) drug class, affecting not only Novartis but also competitors like Amgen and Eli Lilly.
The company disclosed on Tuesday that del-desiran did not meet its primary endpoint in a key cardiovascular trial. This is the second major trial failure in a week for Novartis, further deepening investor concerns. The failure of the drug has cast a shadow over the company’s prospects in the cholesterol treatment market and triggered a broad sell-off in related biotech stocks. Mizuho analysts noted that the selloff in Sarepta shares following the Novartis setback appears overdone, but the market has not yet found a floor. Deutsche Bank downgraded the stock to Hold from Buy, while RBC Capital initiated coverage with a Sector Perform rating. The stock’s sharp decline has also led to a broader market reaction, with Amgen falling 10% as investors reevaluated the entire Lp(a) drug class.
The stock has declined 11.1% over the past eight sessions, moving from $155.21 to $137.98. On September 8, the stock printed two fresh 52-week highs and 21 fresh 52-week lows, highlighting the volatility. The current price of $137.70 is within the 52-week range of $121.57 to $170.46. The stock’s beta of 0.49 suggests it is less volatile than the market, yet the recent drop has been severe. Retail traders on social media platforms have noted the stock’s underperformance, with some calling it oversold. Congressional trades show recent activity, with Senator Alan Armstrong buying shares in the $1,001-$50,000 range on March 30 and March 31.
The stock is currently without an upcoming earnings report, so coverage breadth and analyst reactions to the trial failure will be key to watch in the coming days.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
Novartis investors turn spotlight on M&A after trial setbacks
RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.
Novartis AG’s (NYSE:NVS) pelacarsen failed an important test. Although the experimental medicine lowered lipoprotein(a), or Lp(a), it did not produce a statistically significant reduction in cardiovascular events in the Phase 3 Lp(a)HORIZON study. Bank of America does not believe the result breaks the Novartis (NYSE:NVS) investment thesis. The firm estimates that the failed study creates […]
The drugmaker saw its second late-stage trial miss in days, and Wall Street is now questioning its growth targets.
Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease. Pelacarsen lowered Lp(a), but the study did not meet its primary endpoint of reducing cardiovascular events compared with placebo in […]
NOVARTIS AG ADR (NVS) is drawing unusual attention today. Our newswire has captured 6 stories on NVS across 2 sources in the last 36 hours, with AI sentiment reading bearish (avg 36/100). The most recent driver: "Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure" (Yahoo Top).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of NVS coverage reads 36/100 over 6 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on NVS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier NVS move explainers: 2026-09-09 · 2026-09-08 · 2026-09-02 · 2026-09-01